AbCellera (ABCL) director receives 111,701 share options grant

Rhea-AI Filing Summary

AbCellera Biologics Inc. director John S. Montalbano received a grant of share options giving him the right to buy 111,701 common shares at an exercise price of $5.27 per share. These options vest and become exercisable at the 2027 Annual General Meeting, as long as he continues serving the company. After this grant, he holds 1,141,544 share options in total.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Montalbano John S.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Share option (right to buy)	111,701	$0.00	--

Holdings After Transaction: Share option (right to buy) — 1,141,544 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 111,701 options Exercise price: $5.27 per share Options outstanding after grant: 1,141,544 options +2 more

5 metrics

Options granted 111,701 options Grant to director John S. Montalbano

Exercise price $5.27 per share Option strike price for underlying common shares

Options outstanding after grant 1,141,544 options Total derivative holdings following transaction

Vesting date 2027 Annual General Meeting Options vest and become exercisable at this meeting

Expiration date June 11, 2036 Option award expiration

Key Terms

Share option (right to buy), exercise price, vest and become exercisable, Annual General Meeting

4 terms

Share option (right to buy) financial

"security_title: "Share option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "5.2700" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting"

Annual General Meeting financial

"vest and become exercisable at the 2027 Annual General Meeting"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 01:02 PM Accepted by SEC EDGAR 06/12/2026 - 01:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Montalbano John S.

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	$5.27	06/11/2026		A	V	111,701		06/10/2027(1)	06/11/2036	Common Shares	111,701	$0	1,141,544	D

Explanation of Responses:

1. The shares subject to such option vest and become exercisable at the 2027 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

	Tryn Stimart, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AbCellera (ABCL) director John S. Montalbano report on this Form 4?

John S. Montalbano reported receiving a grant of 111,701 share options in AbCellera Biologics. These options are a form of compensation, giving him the right to buy common shares in the future at a fixed exercise price.

How many AbCellera (ABCL) options were granted to John S. Montalbano and at what price?

John S. Montalbano was granted 111,701 share options, each with an exercise price of $5.27 per common share. This gives him the right, but not the obligation, to buy AbCellera shares at that price once vested.

When do John S. Montalbano’s new AbCellera (ABCL) options vest and expire?

The granted options vest and become exercisable at the 2027 Annual General Meeting, provided he continues serving AbCellera. The options have an expiration date of June 11, 2036, after which any unexercised options will lapse.

How many AbCellera (ABCL) share options does John S. Montalbano hold after this grant?

Following this grant, John S. Montalbano holds a total of 1,141,544 share options in AbCellera Biologics. This figure reflects his aggregate derivative holdings reported in this Form 4 after the new award is included.

Was this AbCellera (ABCL) Form 4 an open-market stock purchase or sale?

No, the Form 4 reports a grant of share options rather than an open-market stock purchase or sale. The transaction is coded as a compensation-related award, not a market trade, and involves no immediate cash outlay or share sale.